Texas Yale Capital Corp. lowered its position in Kenvue Inc. (NYSE:KVUE – Free Report) by 86.2% during the fourth quarter, Holdings Channel reports. The institutional investor owned 10,000 shares of the company’s stock after selling 62,325 shares during the quarter. Texas Yale Capital Corp.’s holdings in Kenvue were worth $172,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Cornerstone Planning Group LLC grew its position in shares of Kenvue by 705.2% in the 3rd quarter. Cornerstone Planning Group LLC now owns 1,554 shares of the company’s stock worth $25,000 after buying an additional 1,361 shares during the last quarter. Physician Wealth Advisors Inc. grew its position in shares of Kenvue by 67.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after buying an additional 618 shares during the last quarter. Elyxium Wealth LLC purchased a new position in shares of Kenvue in the 4th quarter worth approximately $26,000. SBI Securities Co. Ltd. grew its position in shares of Kenvue by 82.4% in the 4th quarter. SBI Securities Co. Ltd. now owns 2,273 shares of the company’s stock worth $39,000 after buying an additional 1,027 shares during the last quarter. Finally, Atlantic Union Bankshares Corp boosted its stake in Kenvue by 184.1% in the 3rd quarter. Atlantic Union Bankshares Corp now owns 2,619 shares of the company’s stock worth $43,000 after purchasing an additional 1,697 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.
Kenvue Stock Performance
Shares of NYSE KVUE opened at $17.39 on Tuesday. The company has a current ratio of 0.98, a quick ratio of 0.70 and a debt-to-equity ratio of 0.67. Kenvue Inc. has a 12 month low of $14.02 and a 12 month high of $23.78. The company has a 50 day simple moving average of $17.40 and a two-hundred day simple moving average of $17.47. The stock has a market cap of $33.38 billion, a price-to-earnings ratio of 20.45, a PEG ratio of 1.31 and a beta of 0.55.
Kenvue Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, May 27th. Shareholders of record on Wednesday, May 13th were paid a dividend of $0.2075 per share. This represents a $0.83 annualized dividend and a yield of 4.8%. The ex-dividend date was Wednesday, May 13th. Kenvue’s payout ratio is presently 97.65%.
Insider Buying and Selling
In other Kenvue news, General Counsel Matthew Orlando sold 38,491 shares of Kenvue stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $17.66, for a total transaction of $679,751.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 1.59% of the company’s stock.
Analyst Upgrades and Downgrades
A number of analysts recently commented on KVUE shares. Canaccord Genuity Group lifted their target price on shares of Kenvue from $17.00 to $18.00 and gave the stock a “hold” rating in a research note on Wednesday, February 18th. Argus upgraded shares of Kenvue to a “hold” rating in a research note on Friday, March 6th. Citigroup lowered their target price on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a research note on Wednesday, April 15th. Weiss Ratings cut shares of Kenvue from a “hold (c)” rating to a “hold (c-)” rating in a research note on Friday. Finally, Zacks Research upgraded shares of Kenvue from a “hold” rating to a “strong-buy” rating in a research note on Friday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and twelve have given a Hold rating to the company’s stock. According to data from MarketBeat, Kenvue presently has a consensus rating of “Hold” and an average target price of $19.33.
Read Our Latest Report on Kenvue
Kenvue Company Profile
Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.
The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.
Read More
- Five stocks we like better than Kenvue
- Why These Three Big Buybacks Are Sending Very Different Signals to Investors
- Drone Stocks Soar As Pentagon Considers Funding, Including a Trump-Linked Name
- Braze Blazes Ahead on Q1 2027 Earnings Beat, Raised Guidance
- Are the 3 Newest Members of the $1 Trillion Market Cap Club the Latest Sign of an AI Bubble?
Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE – Free Report).
Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.
